Anzeige
Mehr »
Donnerstag, 05.02.2026 - Börsentäglich über 12.000 News
Der nächste Durchbruch? Warum dieses Projekt Investoren aufhorchen lässt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von BioPharma Dive

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
13:46Express Scripts reaches 'landmark' settlement with FTC in insulin suit
02:46Eikon Therapeutics nets a $381M IPO amid burst of biotech offerings
MiTrump signs funding bill with PBM reforms, hospital-at-home and telehealth extensions
MiNovo shares tumble by double digits on grim sales outlook
MiLilly soars again as fast-selling weight loss drugs top Wall Street projections
MiEarnings roundup: Amgen vs. FDA, Pfizer's defense and Merck's $70B-in-sales plan
DiPfizer dips on new data for obesity drug acquired in $10B deal
DiFDA launches 'PreCheck' program; AstraZeneca, Acadia drugs set back
MoNovo combination obesity shot meets goal in diabetes trial
MoSanofi drug, inherited from Genzyme, goes 1-for-2 in rare disease trials
MoGSK walks away from pioneering Wave RNA editing drug
MoBuilding a robust in-process testing plan for cell therapy manufacturing success
FrAmgen gives up on its once-prized eczema drug
FrAstraZeneca leans into obesity, striking wide-ranging alliance with China's CSPC
FrPoliticization runs deeper than ever at FDA, risking long-term impacts
29.01.The biopharma industry outlook on 2026: Optimism and tension
29.01.Sanofi expects vaccine sales growth to dip amid 'challenging environment'
29.01.AstraZeneca strengthens China ties with planned $15B investment
29.01.Tenpoint wins FDA nod for combination presbyopia eye drop
28.01.Lilly bets on Seamless, delving further into genetic medicine for hearing loss
28.01.Drugs for cancer, arthritis and HIV on Medicare's list for 2028 price cuts
28.01.Halozyme buys a biotech startup; Cytokinetics launches heart drug
28.01.Regenxbio gene therapy trials suspended by FDA over safety worries
27.01.An immune drug developer raises $50M to finance its eczema drug testing
27.01.FDA lifts hold on an Intellia CRISPR drug trial